4D Molecular Therapeutics entered into a Loan and Security Agreement for a senior secured term loan facility of up to $200 million with Hercules Capital. The company drew $20 million at closing, with additional tranches available upon milestones and lender discretion, maturing on Jun 1, 2031. Interest floats at prime plus 2.00% for Tranche 1A (floor 8.75%) and prime plus 2.50% for other tranches (floor 9.25%), with a $500,000 initial facility charge and 1% charges on later tranches. The facility includes minimum cash and performance covenants and is secured by substantially all assets, including intellectual property.
Agreement details:
- Agreement type: Senior secured term loan facility
- Counterparty: Hercules Capital
- Signed / Effective: Jun 24 2026 / Jun 24 2026
- Duration / Termination: Through Jun 1 2031
- Reason: Strengthen liquidity for development and commercialization
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.